Navigation Links
OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
Date:7/29/2008

hat statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the issuance of a patent covering a pharmaceutical composition of zonisamide in combination with a series of marketed atypical antipsychotics, the efficacy and safety of OREX- 003, and the timing of the initiation of the Company's OZ-101 clinical trial. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Company's business, including, without limitation: the progress and timing of the Company's clinical trials or the development of OREX-003; the potential for adverse safety findings relating to its product candidates to delay or prevent regulatory filings; and Orexigen or its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward- looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
2. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
3. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
5. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
6. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
7. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
8. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
9. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
10. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
11. Organizational Changes at Silence Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... While administrative claims and other ... for a relatively long period of time, there ... use of these ‘big data’ for comparisons of ... today’s powerful computer technology with the plethora of ... holds significant promise for identifying optimal interventions for ...
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... JUPITER, Fla. , July 30, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... enzymes and other proteins for the bioenergy, bio-based ... the appointment of Thomas "Tom" Dubinski as Vice ... responsible for leading the financial and information technology ...
(Date:7/30/2014)... NCERC at Southern Illinois University Edwardsville ... on corn stover pretreatment methods at a U.S. ... D.C. , “Arun’s selection for presentation at ... to the success of our postdoctoral fellowship program,” ... foresight and vision of SIUE and the Illinois ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... coverage and megabase capacity for the next generation ... febit today announced the official ... In several biomedical studies of early access customers ... factors and deep sequencing coverage for a broad ...
... debuts PAKSCAN, a new-look Pharma-packaging leak tester machine for medical pouches ... ... Ireland (PRWEB) March 16, 2009 -- A leak tester ... by Northern Irish company, sepha makes its U.S. market ...
... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, ... approval for PROMETHEUS(R) IBS Diagnostic, the first and only ... novel test incorporates 10 biomarkers, two of which are ... diagnose patients with IBS."One out of five Americans has ...
Cached Biology Technology:Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 2Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 3U.S. Distributor Debut for PAKSCAN - a Pouch & Sachet Leak Tester Machine from Ireland-based Sepha Ltd. 2U.S. Distributor Debut for PAKSCAN - a Pouch & Sachet Leak Tester Machine from Ireland-based Sepha Ltd. 3Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome 2
(Date:7/30/2014)... Professor Steven Chown has been awarded the Scientific ... Excellence in Antarctic Research. , SCAR, an inter-disciplinary ... quality international scientific research in the Antarctic region, ... in the Earth system. The organisation also provides ... System, responsible for governing the region. , The ...
(Date:7/30/2014)... roughly 3,000 pieces is still in its infant stage. ... be of major significance. "Amazingly often, we are findingin ... amber that we found in Baltic amber," explained Bonn ... amber comes from the Baltic Sea region, which is ... are, e.g., the coastal regions of Mecklenburg, Poland and ...
(Date:7/29/2014)... The advanced optical methods and applications for imaging and ... in the neurosciences were the inspiration behind Neurophotonics ... international society for optics and photonics. , The first ... in the United States, and a special section features ... examples of the impact that optics and photonics will ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3
... a scientist with the Oklahoma Medical Research Foundation, has found ... The discovery could have important implications for the treatment of ... findings appear in the April 13 issue of the journal ... go backwards before now," said Gorbsky, who holds the W.H. ...
... produce a substance which prevents the AIDS pathogen HIV from ... of research carried out by scientists at the University of ... years now the hopes for a completely new group of ... 'DCQA'. However, the substance is only available in very small ...
... genetic cause in up to 80 percent of cases, ... nearly 12,000 twin pairs. , The study appears in ... a journal of the American Medical Association. , Margaret ... Letters, Arts, and Sciences, led an international team of ...
Cached Biology News:Rewind, please: Nature paper shows that cell division is reversible 2AIDS drug from sunflowers 2AIDS drug from sunflowers 3Alzheimer's found to be mostly genetic 2
...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
PP2B-Abeta (C-20)...
Biology Products: